Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial-Reference-Cited by-同舟云学术

Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial

Published:2020-10-27 Issue:2 Volume:143 Page:178-187
ISSN:0001-6314
Container-title:Acta Neurologica Scandinavica
language:en
Short-container-title:Acta Neurol Scand

Author:

Cheshmavar Masoumeh¹²^ORCID,Mirmosayyeb Omid¹²^ORCID,Badihian Negin¹³^ORCID,Badihian Shervin⁴^ORCID,Shaygannejad Vahid¹²^ORCID

Affiliation:

1. Isfahan Neurosciences Research Center Alzahra Research Institute Isfahan University of Medical Sciences Isfahan Iran

2. Department of Neurology School of Medicine Isfahan University of Medical Sciences Isfahan Iran

3. Child Growth and Development Research Center Research Institute for Primordial Prevention of Non‐Communicable Disease Isfahan University of Medical Sciences Isfahan Iran

4. Department of Neurology Johns Hopkins University School of Medicine Baltimore MD USA

Funder

Isfahan University of Medical Sciences

Publisher

Wiley

Subject

Clinical Neurology,Neurology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ane.13344

Reference31 articles.

1. Multiple sclerosis, a treatable disease

2. LublinFD ReingoldSC CohenJA et al.Defining the clinical course of multiple sclerosis The 2013 revisions;2014.

3. Secondary progressive multiple sclerosis: current knowledge and future challenges

4. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

5. Epidemiology of multiple sclerosis

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-09-10

2. Rituximab in secondary progressive multiple sclerosis: a meta‐analysis;Annals of Clinical and Translational Neurology;2024-08-26

3. Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Neurology;2024-03-11

4. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-11-30

5. Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab;Basic & Clinical Pharmacology & Toxicology;2023-09-20